EVANIUM Healthcare GmbH is a German life sciences company specializing in the development of enhanced plant-based ingredients for the nutraceutical, food, cosmetic, and pharmaceutical industries.
Founded in 2019 and headquartered in Regensburg, the company employs around 12 people and has developed its proprietary OPTISOLV® technology platform. This IP-protected dual-coating system uses cyclodextrin and phospholipid components to significantly improve the water solubility, stability, and bioavailability of poorly soluble secondary plant compounds such as berberine, curcumin, boswellia, and passiflora.
EVANIUM's ingredients, including OPTISOLV® Berberine which won the Most Innovative Nutraceutical Ingredient award at Vitafoods Europe 2026, enable more effective dosing and broader application formats. The company has secured €2.2 million in seed funding from investors including FoodLabs and Feast Ventures, and maintains partnerships such as an exclusive distribution agreement with WACKER for berberine and a commercial launch with Hevert-Arzneimittel for curcumin.
Operating primarily in Europe with ambitions for global expansion, EVANIUM positions itself as a technology partner providing branded raw materials and contract development services to established industry players. It focuses on addressing bioavailability challenges in natural actives through innovative, natural-material-based formulations.
None yet. When a new project in the record names EVANIUM as owner, partner or investor, it shows here.
Exclusive global distribution for a dual‑coated berberine ingredient that improves absorption and lowers required dose; US launch planned at SupplySide Global.
